DMC Announces 25% Cash Dividend for 2025, Record Date Sept 15
This Aveluro analysis covers DMC on HOSE in the Health Care sector. The classified event type is dividend announcement, with positive sentiment and a deterministic market-impact score of 5.6/10. Aveluro classifies this story as a positive catalyst in the stock's news coverage. Source coverage came from CafeF - Doanh nghiệp, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Overview
Domesco (DMC), listed on HOSE, has announced a 25% cash dividend for 2025, paying 2,500 VND per share. The record date is set for September 15, with payment on October 21. The announcement follows strong H1 2026 results, with net profit up 39% year-on-year.
Key Facts
- Dividend rate: 25% cash, equivalent to 2,500 VND per share.
- Record date: September 15, 2026; ex-rights date: September 14, 2026.
- Payment date: October 21, 2026.
- Total payout: approximately 86.8 billion VND based on 34.7 million outstanding shares.
- Abbott Laboratories (Chile) Holdco Spa, holding 51.69% (nearly 18 million shares), will receive about 45 billion VND.
- SCIC, holding 34.71% (over 12 million shares), will receive about 30 billion VND.
- H1 2026 revenue: nearly 1,039 billion VND, up 6.1% year-on-year.
- H1 2026 net profit: 109.5 billion VND, up 39% year-on-year.
What Happened
Domesco (DMC) has announced a cash dividend for 2025 at a rate of 25%, meaning shareholders will receive 2,500 VND per share. The company set the record date for September 15, with the ex-rights date on September 14. Payment is scheduled for October 21. With over 34.7 million shares outstanding, the total dividend payout is estimated at nearly 86.8 billion VND.
The largest shareholders will receive the majority of the payout. Abbott Laboratories (Chile) Holdco Spa, which owns 51.69% of the company (nearly 18 million shares), will receive approximately 45 billion VND. SCIC, holding 34.71% (over 12 million shares), will receive about 30 billion VND.
The dividend announcement comes alongside strong first-half 2026 results. Net revenue reached nearly 1,039 billion VND, up 6.1% year-on-year, while net profit surged 39% to 109.5 billion VND. The company attributes this growth to a product portfolio review, technology and data integration in management, and tighter cost and cash flow control.
Market Context
DMC closed at 58,000 VND on August 23, 2026. At this price, the 2,500 VND dividend implies a yield of approximately 4.3%. The stock trades on HOSE in the Health Care sector. The dividend announcement and strong earnings come amid a broader Vietnamese market that has seen increased corporate action activity, with other pharmaceutical companies like Dược Hậu Giang also announcing dividends.
Strategic Significance
The dividend payout underscores DMC’s commitment to returning capital to shareholders, supported by robust earnings growth. The 39% net profit increase indicates successful operational improvements and cost management. For long-term investors, the company’s ability to maintain high dividend payouts while growing earnings suggests a stable financial position. The presence of Abbott as a majority shareholder provides strategic backing, potentially aiding in product development and market expansion.
What to Watch
- Q3 2026 earnings release to see if profit growth continues.
- Any updates on product portfolio changes or new product launches.
- Regulatory approvals or changes in the pharmaceutical sector.
- Dividend sustainability: watch for any changes in payout policy.
- Foreign ownership levels, as Abbott’s stake may influence future capital actions.